Akrevia Therapeutics, Inc. logo

Akrevia Therapeutics, Inc.

Akrevia Therapeutics is discovering and developing the next generation of cancer immunotherapies, offering the promise of safer, more efficacious therapeutics Akrevia Therapeutics, is a privately-held biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.akriveiatx.com
Founded2015
Disease Focus
Development StageTechnology
STOCK CODENon Listed
Address
LabCentral 610, 610 Main Street, MA,2139
Cambridge
United States
Email
Contact Number
+1 609-560-0927

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/akrevia” connections=”true” suffix=””]

Akrevias proprietary Aklusion_ platform, based on technology licensed from City of Hope and Thomas Jefferson University, allows potently active biological molecules to be inactive until they encounter the tumor microenvironment. By tailoring pharmacokinetic and pharmacodynamic properties in parallel, Aklusion allows design of molecules with potential best-in-class potency and selectivity.

In Sep 2018, Akrevia Therapeutics, raised $30 Mn in Series A financing, led by F-Prime Capital Partners and Atlas Venture.